Localized Leiomyosarcoma Biomarker Protocol
NCT04925089 is an observational study sponsored by University of Michigan Rogel Cancer Center. As of 21 Nov 2026, it is recruiting participants. It studies Leiomyosarcoma. The registry lists an enrollment of 40 participants at 3 sites in 1 country. The registry lists a start date of 26 Apr 2023 and a primary completion date of 30 Nov 2026. One of its registered investigators has a FindMyKOL profile.
Key facts
Registry attributes as recorded on the ClinicalTrials.gov study record.
| Field | Value |
|---|---|
| Registry ID | NCT04925089 |
| Status | Recruiting |
| Study type | Observational study |
| Lead sponsor | University of Michigan Rogel Cancer Center |
| Enrollment | 40 |
| Registered sites | 3 |
| Countries | 1 |
| Conditions | Leiomyosarcoma |
| Start | 26 Apr 2023 |
| Primary completion | 30 Nov 2026 |
| Study completion | 30 Nov 2026 |
| Last update posted | 2 Jul 2026 |
Registered summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
3 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- University of Michigan
Ann Arbor
Recruiting
- Mayo Clinic
Rochester
Recruiting
- Vanderbilt University Medical Center
Nashville
Recruiting
United States, by state
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study. It may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Questions about NCT04925089
Each answer restates registry values shown on this page.
What is NCT04925089?
NCT04925089 is an observational study sponsored by University of Michigan Rogel Cancer Center. It studies Leiomyosarcoma.
Is NCT04925089 recruiting?
As of 21 Nov 2026, it is recruiting participants. 3 of its 3 sites list their own status as recruiting.
Who leads NCT04925089?
The registry names Scott Schuetze (principal investigator, University of Michigan Rogal Cancer Center) as the overall official.
Where does NCT04925089 run?
The registry lists 3 sites in 1 country. Every site with a stated country is in one country: United States.
When is NCT04925089 expected to complete?
The registry lists a primary completion date of 30 Nov 2026 and a study completion date of 30 Nov 2026. The sponsor last updated the record on 2 Jul 2026.
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.